A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes

Summary

This is a phase 2, multicenter, randomized, double-blind (within dose), placebo controlled, parallel-group, dose-range finding study to evaluate the efficacy and safety of TF0023 spray versus placebo in functional improvement of patients with ischemic strokes under standard of care.

Timeline

Start

2017-03-01

Primary completion

2024-10

Completion

2024-12

Outcome

Outcome not reported

Stopped (Enrollment): “Suspended due to enrollment challenges and business operations.”

Drugs

Indications